(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trade Symbol(s) | Name of each exchange on which registered | ||||||||||||
PRAXIS PRECISION MEDICINES, INC. | |||||||||||
Date: October 2, 2023 | By: | /s/ Marcio Souza | |||||||||
Marcio Souza | |||||||||||
Chief Executive Officer |
Cover |
Oct. 02, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Oct. 02, 2023 |
Entity Registrant Name | PRAXIS PRECISION MEDICINES, INC. |
Amendment Flag | false |
Entity Central Index Key | 0001689548 |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39620 |
Entity Tax Identification Number | 47-5195942 |
Entity Address, Address Line One | 99 High Street |
Entity Address, Address Line Two | 30th Floor |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02110 |
City Area Code | 617 |
Local Phone Number | 300-8460 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | PRAX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
RHY_U=3_ 102P,$% @ ;VM"5Y>*NQS $P( M L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/: (7->=I3W;+T]!;X"O.DQQ0FE( M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJ MD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H M!"DHV1%[A$O\G7 D(G MP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28) MUD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z M_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ ;VM"5R0>FZ*M ^ $ M !H !X;"]? +7_OR4Z?:!1W;J"V\R1&:P;* M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( &]K0E=ED'F2&0$ M ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@ MIAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1 M?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI M>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UP MZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T M,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^ MD &PO=&AE;64O=&AE;64Q M+GAM;%!+ 0(4 Q0 ( &]K0E>O17<4;00 $,1 8 " M@0T( !X;"]W;W)K &PO 7BKL JQ"(6,P$ "(" / M " 740 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !O:T)7)!Z; MHJT #X 0 &@ @ '5$0 >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !O:T)799!YDAD! #/ P $P M @ &Z$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" $ %% ! end
FP-OM=)QWJD@PXX*D>CGVNLPV\ZSJB]W[?2GEI'
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M<6ID%R9Z5,?-D <4QC5G(]?$S3 VRVS<#-HW)#ZG-^F=VE4X%Q@)EM'SGR
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M>/$=^F]?_!]02P,$% @ ;VM"5V EB/9!@ _C( !4 !P>)!
M/U F7+<<5>+77E @7..B>,>XO\J;#2R%A9B49"1)@ZA#B,3Y $0$:KR45$D[
M['G'MQ;[O4 UX6+E( E?.?Q7E6O?:?YXM_5ENP:J& RU1+5OS$KTG%@M,Q(9
M#U9*I4(<]MCSD;E^@9]P/?+EXDWDIG][&]:N6$'WHE?D4EI.([&,ML_K,TF<
MD)QHL&TB)"P-P\K2SUGMQ\"$JXZ#I9Q$M?'M%JH5HOROJKQIUKBX[5QQMS2>
M)]-FPYS+0*3+$K$QPWE,VLQJ4#[:,9YL/FN\'QB3KS<.%W8T/MXLGDAY@0=.
M#AY.M'_:?Y